SCHEMBL6647905

SCHEMBL6647905

CSc1cccc2c(=O)[nH]c(N3CCC(N(C)C)CC3)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.44
TNKS O95271 2/20 0.44
APAF1 O14727 1/20 0.38
CDC25B P30305 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SETD2 Q9BYW2 4/20 0.36
NSD2 O96028 1/20 0.36
PDGFRB P09619 1/20 0.35
FGFR1 P11362 1/20 0.35
KDR P35968 1/20 0.35
WEE1 P30291 1/20 0.34
TIPARP Q7Z3E1 1/20 0.34
EZH2 Q15910 1/20 0.33
HTR2B P41595 2/20 0.33
HTR6 P50406 2/20 0.33
L3MBTL3 Q96JM7 1/20 0.32
KCNH2 Q12809 1/20 0.32
PIM1 P11309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6648367 0.84 TNKS (0.59) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6647334 0.83 TNKS (0.47) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6646697 0.83 PARP1 (0.45) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6643880 0.83 PARP1 (0.47) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6646307 0.83 PARP1 (0.48) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6645174 0.83 SETD2 (0.46) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6645847 0.82 HTR3A (0.44) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6643130 0.81 TNKS (0.45) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6645853 0.81 PARP1 (0.44) PARP1TNKSAPAF1CDC25BCASP3
SCHEMBL6643846 0.81 PARP1 (0.43) PARP1TNKSAPAF1CDC25BCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 US claimed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 EP claimed
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 US disclosed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof PARP11, PARP1, CD38 PARP1 2/4885TNKS 121/4885APAF1 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.